News Updates

More Articles Back to Article

Pfizer wins stake to acquire Seagen with $43B bid

Pfizer has prevailed in the bidding war to acquire antibody-drug conjugate developer Seagen via its $43 billion bid, a deal that is expected to be finalized either late this year or by early 2024. Seagen's ADC tech, combined with Pfizer's size and strength, will help "advance the battle against cancer," according to Pfizer CEO Albert Bourla. BioSpace (San Francisco) (3/13)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!